Zhongyu Lu

机构：Simcere Pharmaceutical (China) · ORCID：0009-0000-6813-7650

发表论文 18 篇 · 总被引 35 次 · h-index 4

代表论文

• Navigating precision: the crucial role of next-generation sequencing recurrence risk assessment in tailoring adjuvant therapy for hormone receptor-positive, human epidermal growth factor Receptor2-negative early breast cancer (2024 · Cancer Biology & Therapy · 被引 6)
• Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study (2024 · Lung Cancer · 被引 5)
• Development and validation of a prognostic and drug sensitivity model for gastric cancer utilizing telomere-related genes (2024 · Translational Oncology · 被引 4)
• Co-Occurring EGFR S645C and EGFR L858R in a Patient with Lung Adenocarcinoma Induced Primary Resistance to Osimertinib (2023 · Lung Cancer Targets and Therapy · 被引 4)
• Anti-PD-1 plus anti-HER2 and chemotherapy showed superior and durable clinical benefit in a patient with advanced salivary duct carcinoma (2022 · Oral Oncology · 被引 4)
• Molecular characteristics of EGFR exon 19 deletion subtypes in NSCLC patients. (2021 · Journal of Clinical Oncology · 被引 4)